GlassScriptPhysician profile
Kerry W Ross
NPI 1932102670
$17,264.93
in general payments reported to CMS, 2019-2025
60 companies · $2,501 in 2025
The $2,501 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,213 · 2020: $1,898 · 2021: $2,338 · 2022: $2,653 · 2023: $2,890 · 2024: $2,771 · 2025: $2,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,162.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,181.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,445.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,413.57 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,193.24 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $1,175.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,058.93 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Abbvie INC. | $911.32 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Novartis Pharmaceuticals Corporation | $856.44 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $747.52 | 2019-2025 | Trulance, Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $721.21 | 2022-2025 | |
| Glaxosmithkline, LLC. | $643.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $620.34 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $495.18 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $429.80 | 2019-2023 | |
| Lundbeck LLC | $381.08 | 2022-2025 | Vyepti, Rexulti |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.